Clinical Trials | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Nous-209 has been developed using the Nouscom's viral vector platform
From cancer research to diagnostic solutions
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Subscribe To Our Newsletter & Stay Updated
